Impact of biologicals on health care Posted 25/10/2019

In a presentation entitled ‘Biosimilar Considerations for Real World Research and Stakeholder Questions’ delivered at the Drug Information Association’s (DIA) Biosimilars Conference, which was held on 23‒24 September 2019 in Bethesda, Maryland, USA, Dr Jaclyn Bosco of IQVIA discussed the impact that biologicals have had on health care.
Examples of the impact that biologicals have had on health care include:
Trastuzumab in human epidermal growth factor receptor 2 positive (HER-2+) breast cancer
Belimumab in lupus
β-interferons in multiple sclerosis
Rituximab in non-Hodgkin’s lymphoma
Anti-tumour necrosis factor-alpha (anti-TNF-α) in inflammatory bowel disease/Crohn’s disease
Targeted biological therapies in rheumatoid arthritis However, despite the great advantages of many biologicals, developing biosimilars of such complicated molecules is not always easy. In the following series of three articles the considerations for real-world research on biosimilars, uptake of biosimilars and the design of biosimilar studies are presented.
Related articles Uptake of biosimilars in different countries varies Considerations for real-world research on biosimilars
Reference Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing. Copyright – Unless otherwise stated all contents of this website are © 2019 Pro Pharma Communications International. All Rights Reserved.
Disease recurrences have halved and mortality has reduced by a third
First treatment advance in 50 years
First disease-modifying therapy; fewer relapses and slowing of disability
New standard of care, increased survival
Revolutionized care: sustained remissions and reduced need for surgery
Reduction in deformity and remission now a realistic goal
Designing fit-for-purpose biosimilar studies
1. Bosco J. Biosimilar considerations for real world research and stakeholder questions. DIA Biosimilars Conference; 2019 Sep 23‒24; Bethesda, Maryland, USA.
Comments (0)
Generics News Research General
- WHO prequalifies antiparasitic APIGenerics/General | Posted 06/12/2019
- EMA recommends approval for two new genericsGenerics/News | Posted 06/12/2019
- FDA generics approvals increasing but not for a...Generics/Research | Posted 29/11/2019
- FDA identifies causes of drug shortages, recomm...Generics/General | Posted 22/11/2019
Biosimilars News Research General
- Australia approves five biosimilars since June...Biosimilars/News | Posted 06/12/2019
- Use of pegfilgrastim copy biological Mecapegfil...Biosimilars/Research | Posted 06/12/2019
- Phase III trials started for bevacizumab and na...Biosimilars/News | Posted 06/12/2019
- WHO launches insulin prequalification programmeBiosimilars/General | Posted 29/11/2019